Global High Pressure Contrast Media Injectors (HPCMI) Market Size (By Type: Single Head Injectors, Dual Head Injectors, and Syringeless Injectors; By Product: Injector Systems and Consumables; By Application: Interventional Cardiology, Endovascular Surgery, Interventional Neuroradiology, and Interventional Radiology; and By End-Use: Hospitals, Ambulatory Surgical Centers, and Clinics) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2022 - 2030
The global market for high pressure contrast media injectors (HPCMI) was valued at US$ 101 Mn in 2021 and is estimated to reach US$ 271 Mn by 2030 with a CAGR of 11.8% from 2022 to 2030.
High pressure contrast media injectors (HPCMIs) are medical imaging devices that inject contrast media into the body to improve tissue visibility during medical imaging tests. This medical equipment has progressed from simple manual injectors to automated systems that not only accurately control the amount of contrast media agent used, but also allow for automated data collecting and individualized doses for each patient, thanks to technological improvements. High-pressure contrast media injectors have progressed from manual injectors with stop-cocks to automated injectors as technology has evolved. These technologies improve precision while also providing a variety of advantages. The market is being driven by the merging of sophisticated technology with classic high-pressure contrast media injectors.
One of the primary forces driving the global HPCMI market is the increased prevalence of chronic diseases such as cardiovascular, neurovascular, and cancer. Cardiovascular diseases (CVDs) are the world's primary cause of mortality, killing an estimated 17.9 million people each year. Cancer has a tremendous impact on society in the United States and around the world. Cancer figures demonstrate what occurs in big groups of people and provide a picture of the disease's impact on humanity across time. Cancer is one of the leading causes of mortality worldwide. In 2018, there were around 18 mn new cancer cases worldwide and over 9 mn cancer-related deaths. Annual new cancer cases are expected to reach 30 mn by 2040, with more than 16 mn cancer-related demise.
There have been various recent advancements in contrast media injector technology, including cost savings from reduced contrast waste and automated data collection for a patient's dose. Automated injector systems now give tailored doses for patients utilizing information from an electronic medical record (EMR) or a picture archiving and communication system, in addition, to accurately controlling the amount of contrast utilized (PACS). Customized injector protocols, an extravasations detection system, and complete communication with the hospital's picture archive and communication system (PACS) and radiology information system (RIS) are all available with the most advanced, IT-enabled contrast injectors. Intravascular contrast media allows magnetic resonance imaging, computed tomography, and angiography to complete a wide range of diagnostic and interventional procedures and is a critical step in any imaging department. The expensive cost of high-pressure contrast media injectors, accessories, and consumables on the other hand, is constraining market expansion.
Type, product, application, end-use, and region are the five segments of the global high pressure contrast media injectors (HPCMI) industry. The type segment is further bifurcated into dual head injectors, single head injectors, and syringeless injectors. Based on product, the segmentation includes injector systems (CT injector and MRI injector) and consumables. Interventional cardiology, interventional neuroradiology, endovascular surgery, and interventional radiology are the categorization of application segments. Furthermore, the end-use segment is categorized into hospitals, ambulatory surgical centers, and clinics.
Global High Pressure Contrast Media Injectors (HPCMI) Market Regional Competition
North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa are the segmentation of the global high pressure contrast media injectors (HPCMI) industry. Among all the regions, North America acquired the lion’s share in 2021. The rising senior population, rising cancer prevalence and accompanying growth in cancer diagnostic instruments, and technological advancements in high-pressure contrast media injector techniques are all contributing to the region's rapid growth. On the other hand, the Europe market is estimated to observe the substantial growth rate (CAGR) throughout the projected years 2022 – 2030. The region's market is predicted to rise due to rising demand for medical devices, increased research and development in the field of medical technology, and an increase in the number of hospitals dedicated to the senior population.
Global High Pressure Contrast Media Injectors (HPCMI) Industry Segment Analysis
Market By Type
· Single Head Injectors
· Syringeless injectors
· Dual Head Injectors
Market By Product
· Injector Systems
o CT Injector
o MRI Injector
Market By Application
· Interventional Cardiology
· Interventional Radiology
· Interventional Neuroradiology
· Endovascular Surgery
Market By End-Use
· Ambulatory Surgical Centers
High Pressure Contrast Media Injectors (HPCMI) Market Leading Companies
This section of the report identifies the market's major players. Apollo RT Co. Ltd., Bayer, Bracco Group, GE Healthcare, Guerbet Group, Medtronic AG, NemotoKyorindo Co., Ltd., Ulrich GmbH & Co. KG, and Sino Medical-Device Technology Co. and the key companies mentioned in the research.
High Pressure Contrast Media Injectors (HPCMI) Market Regions
· Rest of Europe
· Rest of Latin America
· South Korea
· Rest of Asia-Pacific
Middle East & Africa
· South Africa
· Rest of Middle East & Africa